Here’s Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power (DPW)

- Biotricity is developing the Bioflux remote cardiac monitoring system that could disrupt the $22 billion cardiac monitoring market.

- U.S. FDA and CMS recently announced improved reimbursement for remote monitoring devices such as BTCY’s.

- USFDA clearance of Bioflux could come as soon as next week and BTCY should make a big move when announced.

- Companies like BTCY are positioned to benefit from a massive shift towards high-tech, high-value products like this device.

Between the United States Food and Drug Administration (USFDA) and the Centers for Medicare & Medicaid Services (CMS), the signals are all there - remote patient monitoring is on the verge of a major market expansion, and Biotricity (OTCMKST:BTCY) exemplifies the kind of company that can benefit. Biotricity’s Bioflux remote cardiac monitor is ...View the full post at: Here’s Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power (DPW) ...

Related Articles:

Canadian Junior Miners Seeing Major Increase in Value

The Top 7 Jurisdictions Likely to Legalize Nutrients in 2018

Option Trading Before Earnings in Micron Technology (MU)

800 Percent Revenue Growth Could Imply 200-300 Percent Returns For This Small Cap Stock

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks